Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Janux Therapeutics Inc (NQ: JANX )

48.82 -1.49 (-2.96%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Janux Therapeutics Inc

< Previous 1 2 3 4 5 Next >
Why Janux Therapeutics Shares Rose 33.1% This Week
The clinical-stage biotech company just began its first clinical trial. 
Via The Motley Fool
Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer
From Janux Therapeutics, Inc.
Via Business Wire
7 Short-Squeeze Stocks to Buy for Contrarian Investors
The pessimists may have bitten off more than they can chew for these intriguing contrarian market ideas. 
Via InvestorPlace
Janux Therapeutics Appoints Brenda Van Vreeswyk as Head of Human Resources
From Janux Therapeutics, Inc.
Via Business Wire
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial... 
Via Benzinga
Janux Therapeutics Appoints Winston Kung to Board of Directors
From Janux Therapeutics, Inc.
Via Business Wire
Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session
Gainers 
Via Benzinga
Janux Therapeutics to Participate and Present at Upcoming Investor Conferences in September
From Janux Therapeutics, Inc.
Via Business Wire
Why Minerva Neurosciences Shares Traded Higher By Over 66%; Here Are 78 Biggest Movers From Yesterday
Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) shares gained 66.5% to close at $7.51 after Point72 Asset Management reported an 8.8% passive stake in the company. 
Via Benzinga
Advance Auto Parts, Nordstrom And Other Big Stocks Recording Losses On Wednesday
U.S. stocks closed higher with the Nasdaq Composite gaining 50 points on Wednesday. Here is the list of some big stocks moving lower in the previous session. 
Via Benzinga
Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
From Janux Therapeutics, Inc.
Via Business Wire
Zendesk, Quotient, + 40 Stocks Moving In Friday's Mid-Day Session
Gainers USA Truck, Inc. (NASDAQ: USAK) shares jumped 111% to $30.76. DB Schenker and USA Truck announced plans to combine and create premier North American transportation solutions provider. 
Via Benzinga
Looking Into Janux Therapeutics's Return On Capital Employed
According to Benzinga Pro data, during Q1, Janux Therapeutics (NASDAQ:JANX) posted sales of $1.59 million. Earnings were up 0.04%, but Janux Therapeutics still reported an overall loss of $13.41... 
Via Benzinga
Janux Therapeutics to Present at 2022 Jefferies Global Healthcare Conference
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Announces FDA Clearance of Investigational New Drug Application for JANX007, a PSMA-TRACTr for Metastatic Castration-Resistant Prostate Cancer
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics to Present Preclinical Data at the 18th Annual PEGS Boston for PSMA-TRACTr and EGFR-TRACTr
From Janux Therapeutics
Via Business Wire
Janux Therapeutics's Return On Capital Employed Overview
Janux Therapeutics (NASDAQ:JANX) brought in sales totaling $1.62 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 24.61%, resulting in a... 
Via Benzinga
Janux Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics to Present Virtually at the H.C. Wainwright BioConnect Conference
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics Reports Business Highlights and Third Quarter 2021 Financial Results
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics to Present Virtually at Upcoming Investor Conferences
From Janux Therapeutics, Inc.
Via Business Wire
50 Biggest Movers From Yesterday
Gainers Red Cat Holdings, Inc. (NASDAQ: RCAT) shares surged 50% to close at $3.60 on Monday after the company said its subsidiary, Skypersonic, Inc, won a five-year contract from... 
Via Benzinga
48 Biggest Movers From Friday
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by... 
Via Benzinga
Janux Therapeutics Appoints Ron Barrett, Ph.D., and Alana McNulty to Board of Directors
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investor Conference
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics Appoints Shahram Salek-Ardakani, Ph.D., Chief Scientific Officer
From Janux Therapeutics
Via Business Wire
84 Biggest Movers From Friday
Gainers Sphere 3D Corp. (NASDAQ: ANY) shares surged 41.3% to close at $4.86 on Friday after the company inked an agreement with turnkey mining solutions provider Hertford... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2021
Upgrades According to Citigroup, the prior rating for ORIC Pharmaceuticals Inc (NASDAQ: 
Via Benzinga
The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision, Conference Presentations In A Light Week
Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.